Home > Treatment Options > Tumor Suppressors > Clinical Trials >
Pasireotide
Last Updated: 03/28/17
Status: Determined Ineffective for NF2
Index
- Basic Information Trials
- Side Effects
| Other Names | SOM230, SOM 230, UNII-98H1T17066 |
|---|---|
| Prescription Information | SOM230 |
| Trade Name | Orphan Drug |
| Pharmaceutical Company | Novartis |
| Treatment By | IV |
| Effect Expectation | Brain Meningiomas |
| Pipeline Data | Novartis |
| Inhibitor | Small Somatostatin (SST) |
| SST is a Growth Hormone (GH) Inhibited | |
| Molecular Formula | C58H66N10O9 |
| IUPAC Name | [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate |
1. Basic Information
Treatment with Pasireotide, also known as SOM230, is meant to shrink brain Meningiomas tumor mass.
Many tumor suppressors for NF2 effect primarily brain Schwannoma tumors that are doing damage to different Cranial Nerves. However Meningiomas are issues as well.
Schwannoma tumors damage the nerves they grown on which is dangerous, but as Meningiomas grow larger, they are just as dangerous as they cause pressure on brain matter and result in different brain function issues. Issues developed would be based on the exact location and possibly size of each problematic tumor.
2. Trials
- Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma - www.ClinicalTrials.gov
- SOM230-C Trial - Meningiomas - PHASE II Study of Monthly SOM230 for Recurrent or Progressive Meningioma (IRB#19611) - Cedars-Sinai Medical Center / Cochran Brain Tumor Center
3. Side Effects
- Blood Pressure
- Cholesterol Value
- Weight Loss
- Diarrhea
- Abdominal Discomfort
- Nausea
- Vomiting
